EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Martins-Branco D, Lobo-Martins S, Aftimos P, Pereira B, Vasconcelos de Matos L, Fernandes L, Campôa E, Nader-Marta G, Moreau M, Taylor D, Duhoux FP, Simões P, Garcia AR, Patel V, Confente C, Alpuim Costa D, Pereira J, Santos C, Paesmans M, Sarmento F, Gantes Padrão T, Simão D, Bandarra D, Sousa B, Brito M, Gombos A, Ameye L, de Azambuja E

Open source

DOI: 10.1007/s10549-026-08012-5
Published: 2026 Jul 10
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08012-5,
  title = {EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.},
  author = {Martins-Branco D and Lobo-Martins S and Aftimos P and Pereira B and Vasconcelos de Matos L and Fernandes L and Campôa E and Nader-Marta G and Moreau M and Taylor D and Duhoux FP and Simões P and Garcia AR and Patel V and Confente C and Alpuim Costa D and Pereira J and Santos C and Paesmans M and Sarmento F and Gantes Padrão T and Simão D and Bandarra D and Sousa B and Brito M and Gombos A and Ameye L and de Azambuja E},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-08012-5},
  url = {https://doi.org/10.1007/s10549-026-08012-5}
}

RIS

TY  - JOUR
TI  - EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.
AU  - Martins-Branco D
AU  - Lobo-Martins S
AU  - Aftimos P
AU  - Pereira B
AU  - Vasconcelos de Matos L
AU  - Fernandes L
AU  - Campôa E
AU  - Nader-Marta G
AU  - Moreau M
AU  - Taylor D
AU  - Duhoux FP
AU  - Simões P
AU  - Garcia AR
AU  - Patel V
AU  - Confente C
AU  - Alpuim Costa D
AU  - Pereira J
AU  - Santos C
AU  - Paesmans M
AU  - Sarmento F
AU  - Gantes Padrão T
AU  - Simão D
AU  - Bandarra D
AU  - Sousa B
AU  - Brito M
AU  - Gombos A
AU  - Ameye L
AU  - de Azambuja E
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-08012-5
UR  - https://doi.org/10.1007/s10549-026-08012-5
ER  -

APA

D, M., S, L., P, A., B, P., L, V. D. M., L, F., E, C., G, N., M, M., D, T., FP, D., P, S., AR, G., V, P., C, C., D, A. C., J, P., C, S., M, P., F, S., T, G. P., D, S., D, B., B, S., M, B., A, G., L, A., & E, D. A. (2026). EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08012-5

Source records

pubmed · retrieved 2026-09-25T15:13:51.683Z